Evercore ISI lowered the firm's price target on Caris Life Sciences to $25 from $30 and keeps an Outperform rating on the shares. The firm's Q2 preview for MedTech, Life Sciences Tools, and Diagnostics highlights generally healthy procedure volumes and capital expenditure trends across the sector, the analyst tells investors in a research note.
